Urinary tobacco smoke-constituent biomarkers for assessing risk of lung cancer

Cancer Research

Volumn 74, Issue 2, 2014, Pages 401-411

  Yuan, Jian Min ^a,b   Butler, Lesley M ^a,b   Stepanov, Irina ^c   Hecht, Stephen S ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BUTADIENE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 4 TETRAHYDROXY 1,2,3,4 TETRAHYDROPHENANTHRENE; ACROLEIN; BENZENE; BIOLOGICAL MARKER; CARCINOGEN; COTININE; CROTONALDEHYDE; GLUCURONIDE; NICOTINE; POLYCYCLIC AROMATIC HYDROCARBON; TOBACCO SMOKE; UNCLASSIFIED DRUG;

CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOGENICITY; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENVIRONMENTAL EXPOSURE; HUMAN; LUNG CANCER; PASSIVE SMOKING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; URINE LEVEL;

BIOLOGICAL MARKERS; CARCINOGENS; COTININE; GLUCURONIDES; HUMANS; LUNG NEOPLASMS; MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; NICOTINE; NITROSAMINES; PHENANTHRENES; POLYCYCLIC HYDROCARBONS, AROMATIC; PROSPECTIVE STUDIES; PYRIDINES; RISK; RISK ASSESSMENT; SMOKE; TOBACCO;

EID: 84892947651     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3178     Document Type: Review

References (62)

1. WHO. WHO global report: mortality attributable to tobacco. Geneva, Switzerland: World Health Organization; 2012. Available from: http://whqlibdoc.who.int/publications/2012/9789241564434-eng.pdf.
2. Centers for Disease Control and Prevention. Consumption of cigarettes and combustible tobacco-United States, 2000-2011. MMWR Morb Mortal Wkly Rep 2012;61:565-9.
3. Food and Agriculture Organization of the United Nations. Projections of tobacco production, consumption and trade to the year 2010. Rome, Italy: FAO; 2003. Available from: http://www.fao.org/docrep/006/y4956e/y4956e00. htm#Contents.
4. Guindon GE, Boisclair D. Past, current and future trends in tobacco use. Economics of tobacco control paper no. 6. Health, Nutrition and Population (HNP) discussion paper. 2003 Feb. Available from: http://siteresources.worldbank.org/ HEALTHNUTRITIONANDPOPULATION/Resources/281627-1095698140167/Guindon-PastCurrent- whole.pdf.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
7. International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risk to humans. Vol. 83. Lyon, France: IARC Scientific Publications; 2004.
8. Thun MJ, Henley SJ, Calle EE. Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene 2002;21:7307-25.
9. Hecht SS. Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. Nicotine Tob Res 2012;14:18-28.
10. Hecht SS. Tobacco carcinogens, their biomarkers and tobaccoinduced cancer. Nat Rev Cancer 2003;3:733-44.
11. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79-115.
12. Benowitz NL, Hukkanen J, Jacob P III. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009:29-60.
13. Benowitz NL, Dains KM, Dempsey D, Herrera B, Yu L, Jacob P III. Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine Tob Res 2009;11:954-60.
14. International Agency for Research on Cancer. Smokeless tobacco and tobacco-specific nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 89. Lyon, France: IARC Scientific Publications; 2007.
15. Hecht SS. Biochemistry, biology, and carcinogenicity of tobaccospecific N-nitrosamines. Chem Res Toxicol 1998;11:559-603.
16. Belinsky SA, Foley JF, White CM, Anderson MW, Maronpot RR. Dose-response relationship between O6-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone. Cancer Res 1990;50:3772-80.
17. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002;23:907-22.
18. Stepanov I, Hecht SS. Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. Cancer Epidemiol Biomarker Prev 2005;14:885-91.
19. Knezevich A, Muzic J, Hatsukami DK, Hecht SS, Stepanov I. Nornicotine nitrosation in saliva and its relation to endogenous synthesis of N'-nitrosonornicotine in humans. Nicotine Tob Res 2013;15:591-5.
20. Wu W, Zhang L, Jain RB, Ashley DL, Watson CH. Determination of carcinogenic tobacco-specific nitrosamines in mainstream smoke from U. S.-brand and non-U. S.-brand cigarettes from 14 countries. Nicotine Tob Res 2005;7:443-51.
21. Stanton MF, Miller E, Wrench C, Blackwell R. Experimental induction of epidermoid carcinoma in the lungs of rats by cigarette smoke condensate. J Natl Cancer Inst 1972;49:867-77.
22. Hoffmann D, Wynder EL. A study of tobaccocarcinogenesis. XI. Tumor initiators, tumor accelerators, and tumor promoting activity of condensate fractions. Cancer 1971;27:848-64.
23. Rodgman A, Perfetti TA. The chemical components of tobacco and tobacco smoke. Boca Raton, FL: CRC Press; 2009.
24. International Agency for Research on Cancer. Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 92. Lyon, France: IARC Scientific Publications; 2010.
25. Hecht SS, Carmella SG, Le KA, Murphy SE, Li YS, Le C, et al. Effects of reduced cigarette smoking on levels of 1-hydroxypyrene in urine. Cancer Epidemiol Biomarkers Prev 2004;13:834-42.
26. Hecht SS, Chen M, Yagi H, Jerina DM, Carmella SG. r-1, t-2, 3, c-4-Tetrahydroxy-1, 2, 3, 4-tetrahydrophenanthrene in human urine: a potential biomarker for assessing polycyclic aromatic hydrocarbon metabolic activation. Cancer Epidemiol Biomarker Prev 2003;12:1501-8.
27. Carmella SG, Chen M, Yagi H, Jerina DM, Hecht SS. Analysis of phenanthrols in human urine by gas chromatography-mass spectrometry: potential use in carcinogen metabolite phenotyping. Cancer Epidemiol Biomarkers Prev 2004;13:2167-74.
28. Carmella SG, Chen M, Han S, Briggs A, Jensen J, Hatsukami DK, et al. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem Res Toxicol 2009;22:734-41.
29. Yuan JM, Butler LM, Gao YT, Murphy SE, Carmella SG, Wang R, et al. Urinary metabolites of a polycyclic aromatic hydrocarbon and volatile organic compounds in relation to lung cancer development in lifelong never smokers in the Shanghai Cohort Study. Carcinogenesis. 2013 Nov. 25. [Epub ahead of print].
30. Yuan JM, Gao YT, Murphy SE, Carmella SG, Wang R, Zhong Y, et al. Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. Cancer Res 2011;71:6749-57.
31. Hecht SS, Yuan J-M, Hatsukami D. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Toxicol 2010;23:1001-8.
32. International Agency for Research on Cancer. 1, 3-Butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl chloride and vinyl bromide). IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 97. Lyon, France: IARC Scientific Publications; 2008.
33. International Agency for Research on Cancer. Some industrial chemicals. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Vol. 60. Lyon, France: IARC Scientific Publications; 1994.
34. International Agency for Research on Cancer. Acrolein. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 63. Lyon, France: IARC Scientific Publications; 1995.
35. International Agency for Research on Cancer. Dry cleaning, some chlorinated solvents and other industrial chemicals. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 63. Lyon, France: IARC Scientific Publications; 1995.
36. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339:943-6.
37. Yuan JM, Ross RK, Wang XL, Gao YT, Henderson BE, Yu MC. Morbidity and mortality in relation to cigarette smoking in Shanghai, China. A prospective male cohort study. JAMA 1996;275:1646-50.
38. Ellard GA, de Waard F, Kemmeren JM. Urinary nicotine metabolite excretion and lung cancer risk in a female cohort. Br J Cancer 1995;72:788-91.
39. Yuan JM, Koh WP, Murphy SE, Fan Y, Wang R, Carmella SG, et al. Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res 2009;69:2990-5.
40. Boffetta P, Clark S, Shen M, Gislefoss R, Peto R, Andersen A. Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarker Prev 2006;15:1184-8.
41. Church TR, Anderson KE, Caporaso NE, Geisser MS, Le CT, Zhang Y, et al. A prospectively measured serum biomarker for a tobaccospecific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarker Prev 2009;18:260-6.
42. Timofeeva MN, McKay JD, Smith GD, Johansson M, Byrnes GB, Chabrier A, et al. Genetic polymorphisms in 15q25 and 19q13 loci, cotinine levels, and risk of lung cancer in EPIC. Cancer Epidemiol Biomarker Prev 2011;20:2250-61.
43. Avila-Tang E, Al-Delaimy WK, Ashley DL, Benowitz N, Bernert JT, Kim S, et al. Assessing secondhand smoke using biological markers. Tob Control 2013;22:164-71.
44. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y. Comparison of tests used to distinguish smokers from nonsmokers. Am J Public Health 1987;77:1435-8.
45. Balbo S, James-Yi S, Johnson CS, O'Sullivan MG, Stepanov I, Wang M, et al. (S)-N'-Nitrosonornicotine, a constituent of smokeless tobacco, is a powerful oral cavity carcinogen in rats. Carcinogenesis 2013;34:2178-83.
46. Stepanov I, Sebero E, Wang R, Gao YT, Hecht SS, Yuan JM. Tobaccospecific N-nitrosamine exposures and cancer risk in the Shanghai Cohort Study: remarkable coherence with rat tumor sites. Int J Cancer. 2013 Oct. 31. [Epub ahead of print].
47. Yuan JM, Knezevich AD, Wang R, Gao YT, Hecht SS, Stepanov I. Urinary levels of the tobacco-specific carcinogen N'-nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers. Carcinogenesis 2011;32:1366-71.
48. Yuan JM, Gao YT, Wang R, Chen M, Carmella SG, Hecht SS. Urinary levels of volatile organic carcinogen and toxicant biomarkers in relation to lung cancer development in smokers. Carcinogenesis 2012;33:804-9.
49. Hecht SS, Carmella SG, Le KA, Murphy SE, Boettcher AJ, Le C, et al. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides in the urine of infants exposed to environmental tobacco smoke. Cancer Epidemiol Biomarker Prev 2006;15:988-92.
50. Stepanov I, Hecht SS, Duca G, Mardari I. Uptake of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by Moldovan children. Cancer Epidemiol Biomarker Prev 2006;15:7-11.
51. Chung FL, Kelloff G, Steele V, Pittman B, Zang E, Jiao D, et al. Chemopreventive efficacy of arylalkyl isothiocyanates and N-acetylcysteine for lung tumorigenesis in Fischer rats. Cancer Res 1996;56:772-8.
52. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the U. S. preventive services task force recommendation. Ann Intern Med 2013;159:441-20
53. National Lung Screening Trial Research Team Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
54. Hecht SS, Trushin N, Rigotty J, Carmella SG, Borukhova A, Akerkar S, et al. Complete inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone- induced rat lung tumorigenesis and favorable modification of biomarkers by phenethyl isothiocyanate. Cancer Epidemiol Biomarker Prev 1996;5:645-52.
55. Morse MA, Amin SG, Hecht SS, Chung FL. Effects of aromatic isothiocyanates on tumorigenicity, O6-methylguanine formation, and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Cancer Res 1989;49:2894-7.
56. Hecht SS, Chung FL, Richie JP Jr, Akerkar SA, Borukhova A, Skowronski L, et al. Effects of watercress consumption on metabolism of a tobacco-specific lung carcinogen in smokers. Cancer Epidemiol Biomarkers Prev 1995;4:877-84.
57. Burns DM, Dybing E, Gray N, Hecht S, Anderson C, Sanner T, et al. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization Tobacco Regulation Proposal. Tob Control 2008;17:132-41.
58. Hecht SS, Stepanov I, Hatsukami DK. Major tobacco companies have technology to reduce carcinogen levels but do not apply it to popular smokeless tobacco products. Tob Control 2011;20:443.
59. Hatsukami DK, Kotlyar M, Hertsgaard LA, Zhang Y, Carmella SG, Jensen JA, et al. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction 2010;105:343-55.
60. Morbidity and Mortality Weekly Report (MMWR). Notes from the field: electronic cigarette use among middle and high school students-United States, 2011-2012. MMWR Morb Mortal Wkly Rep 2013;62:729-30.
61. Stepanov I, Carmella SG, Briggs A, Hertsgaard L, Lindgren B, Hatsukami D, et al. Presence of the carcinogen N'-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res 2009;69:8236-40.
62. Stepanov I, Carmella SG, Han S, Pinto A, Strasser AA, Lerman C, et al. Evidence for endogenous formation of N'-nitrosonornicotine in some long-term nicotine patch users. Nicotine Tob Res 2009;11:99-105.